Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!

     

     

    Main Contacts  Pro EuroDILINet

    General enquiries: info@proeurodilinet.eu


    Dr Raul ANDRADE
    Chair

    Prof Guruprasad AITHAL
    Vice Chair

    Dr Rossella MAGLI
    Science officer

    Ms Nathalie WARENGHIEN
    Administrative officer

    1st Working Groups Meeting – 2nd CG & MC – Training School Málaga 14-15 March 2019

    1st Working Groups Meeting – 2nd CG & MC – Training School Málaga 14-15 March 2019
    09/23/2018 Aurelie Papineau

    1st Working Groups Meeting, 2nd CG & MC – Training School.

    Málaga 14-15 March 2019

    Venue

    Hotel

    Scientific programmes

    Working groups Meeting

    1st Working Groups Meeting

    Date: 14 March 2019

    Time: 08.30h to 18.30h

    Venue:  Aula Magna, School of Medicine, Blvd L Pasteur 32, 29071. Málaga, Spain

     

    8.30               Registration

    8.45 – 9.15       PRO-EURODILI Welcome

    9.15-9.45        Chair: Raul J Andrade, Spain

    Plenary Lecture: Michael Manns, Germany

    How European hepatologists can benefit from the Pro Euro DILI Net Cost?

    10.00-11.00      Short presentations from WGs Leaders

    Speakers:

    WG1 Prof. Jane Groove, Nottingham, UK

    WG2   Prof. Gerd A Kullak Ublick, Switzerland

    WG3   Prof. José Carlos Fernández Checa, Spain

    WG4 Prof. Einar Stefán Björnsson, Iceland

    WG5 Dr Simona Stankevičiūtė, Lithuania

     

    11:00- 11:20  Coffee Break

     

    11.20-12.30   Break-out Sessions: WGs Meeting

    Each WG Leader: Introduction, Tour de Table

    Aims, tasks & Deliverables

     

    12.30-13.00    Chair: Guruprasad Aithal

    Plenary Lecture: Ann Daly, Newcastle, UK

    DILI as a polygenic disease. International Consortia and DILI initiatives to strengthen knowledge development

     

    13.00-14.30    Lunch Break

     

    14.30-15.00    Chair: Carmen Peralta, Spain

    Plenary Lecture: Leo Nelson, Edinburgh, Scotland

    Human Models for improved prediction of DILI

     

     15.00-16.45   Break-out sessions

    WG1, WG2, WG3, WG4, WG5

     

    16.45-17.00    Coffee Break

     

    17.00-17.30   Chair: Joanna Miranda, Portugal

    Plenary Lecture

    Andreas Benesic, Munich, Germany

                          Outreaching biotechnological enterprises in DILI

     

    17.30-18.30   Plenary session (results and conclusion) All

    2nd Core Group Meeting

    COST Action CA17112

    Action Title: Prospective European Drug-Induced Liver Injury Network

    Draft Agenda

    Second Core Group Meeting

    Málaga, Spain

    15th March 2019

    08:30 – 10:00

    Venue: Biblioteca Departamento de Farmacología, Facultad de Medicina, Málaga

    1. Approval of CG#1 minutes (2019 January 9th, Lisbon, Portugal)
    2. Report about PRO EURO DILI NET management tasks and Implementation of COST policies
    3. Internal evaluation of the 1st Grant Period
    4. Discussion about management rules for activities 2019/20
      1. STSMs
      2. Training schools (survey)
      3. ITC Conference Grant
      4. Monothematic Conference planning
    5. Action implementation planning
      1. Monitoring of the Objective Achievement Indicators for MoU Objectives
      2. Activity and budget planning (Work and Budget Plan preparation)
      3. Dissemination strategy/ planning (Publications and outreach activities)
    6. Any Other Business
    7. Closing

    2nd Management Committee Meeting

    COST Action CA17112

    Action Title: Prospective European Drug-Induced Liver Injury Network

    Draft Agenda

    Management Committee Meeting

    Málaga, Spain

     

    15th March 2019.

    10:30 – 13:00

    Venue: Seminar, Department of Pharmacology, School of Medicine.

    1. Welcome to participants
    2. Verification of the presence of two-thirds of the Participating COST Countries or, if applicable, a quorum
    3. Adoption of agenda
    4. Approval of minutes and matters arising of last meeting
    5. Update from the Action Chair
    6. a) Status of Action: start and end dates of Action, participating COST countries, participating NNC/ IPC institutions and Specific Organisations.
    7. b) Short Term Scientific Missions (STSM): List of centres, topics, dates and ready to take applications
    8. c) Training Schools: Rules and topics
    9. Update from the Grant Holder: Action budget status
    10. Update from the COST Association: Science officer and Administrative Officer
    11. Monitoring of the Action
    12. Implementation of COST policies on:
    13. a) Promotion of gender balance and Early Career Investigators (ECI)
    14. b) Inclusiveness and Excellence (see below list of Inclusiveness Target Countries)
    15. Follow-up of MoU objectives: progress report of working groups
    16. Scientific planning
    17. a) Scientific strategy (MoU objectives, GP Goals, WG tasks and deliverables)
    18. b) Action Budget Planning
    19. c) Long-term planning (including anticipated locations and dates of future activities)
    20. d) Dissemination planning (Publications and outreach activities)
    21. Requests to join the Action from:
    22. a) COST countries
    23. b) Institutions in Near Neighbouring Countries, International Partner Countries, and/or Specific Organisations
    24. AOB
    25. Location and date of next meeting
    26. Summary of MC decisions
    27. Closing

    Training School

    1st TRAINING COURSE, ACTION COST 17-112

    PRO EURO DILI NET

    ASSESSMENT OF DRUG-INDUCED LIVER INJURY: KEY RULES AND COMMON PITFALLS. HOW TO MAKE A CLINICAL NARRATIVE

     

    We are currently working in order to achieve ERT (Eurotox) recognition for the course.

    Date: 15 March 2019

    Time: 08.30h to 19.00h

    Venue:  Aula Magna, School of Medicine, Blvd L Pasteur 32, 29071. Málaga, Spain

    Registration form: https://goo.gl/forms/MspTgxQb4ts3NSNJ3

     

    Overview

    Idiosyncratic drug-induced liver injury (DILI) is an acute adverse hepatic reaction that occurs in only a small proportion of individuals exposed to a drug, it is unexpected from the known pharmacological action of the agent, leading to illness, disability, hospitalization, including life threatening liver failure and death or need for liver transplantation. DILI represents a major challenge for clinicians, the pharmaceutical industry and regulatory agencies worldwide as it stands as one of the main causes of drug attrition during development and the adoption of regulatory measures to improve clinical safety. There is a clear need for a deeper understanding of this complex and intriguing disorder.

    To achieve this objective regulatory bodies and professionals from the pharmacovigilance arena should develop skills in DILI recognition through an update on the key criteria used for DILI diagnosis and its in-depth phenotyping. This course will combine conceptual talks with problem-solving learning exercises to help translate the knowledge into a real world setting.

    Learning Objectives

    This training course in DILI will enable to

    • Make a proper DILI case definition and phenotype classification and a case narrative
    • Recognize the drugs most commonly involved in DILI and the scientific evidence to support it
    • Work-out the minimal elements to make a proper DILI case adjudication
    • Balance the value of the diagnostic scales used for DILI assessment
    • Recognize the role of liver tests monitoring in preventing/minimizing DILI risk

     

    Assessment

    The assessment is based on a written MCQ examination on the last day of the course

     

    Scientific Program (Agenda)

    Day 15 March 2019

    08.30                        REGISTRATION

    08.45h                      Introduction, opening statements and presentations

    Raúl J Andrade

    09.00 / 09.30         Risk Minimization Strategies. Why DILI initiative is important?

    Herve Le Louet, France

    09.30 / 10.00         Drug-induced liver injury: general concepts, interpretation of  liver tests and common mistakes.

    Raúl J Andrade, Spain

    10.00 /10.30        COFFEE BREAK

    10.30 / 11.15             Case definition and phenotypes. Grading Severity and Predicting outcome in DILI. The benefits of Registries

                                      Guruprasad Aithal, UK       

    11.15 / 12.00             New approaches to DILI identification using electronic medical  records

    Ayako Suzuki, USA

    12.00 / 13.15           How to face a DILI suspicion

    A clinical algorithm for diagnostic approach:

                                     Mercedes Robles, Spain

    Clinical Vignettes

                                     Guido Stirnimann, Switzerland

    13.15 / 14.30        LUNCH

    14.30 / 15.00          Minimal data elements for proper DILI adjudication. Case study  on a published DILI case.

                                    M Isabel Lucena, Spain

    15.00 / 15.45           How to prepare a case narrative

                                    Einar Björnsson, Iceland     

    15.45 / 16.15         COFFEE BREAK     

    16.15 / 16.45            Causality assessment scales: strengths and weaknesses

    Miren Garcia-Cortes, Spain

    16.45 / 18.30           Introduction to breakout groups for assessment of DILI cases (Spain)

                                     Miren Garcia-Cortes, Camilla Stephens, Aida Ortega-Alonso, Mercedes Robles-Diaz, Judith Sanabria, Spain

    18.30 / 19.00           Closing remarks and Assessment (written MCQs)

     

    Documents